Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Bronchial glandular epithelium refers to the cellular lining of submucosal glands within the bronchial wall of the respiratory tract. It consists primarily of mucous cells and serous cells, supported by myoepithelial cells, all derived from epithelial origin. These cells secrete mucus and serous fluid into the airways, contributing to the airway surface liquid, which plays a critical role in humidifying inhaled air, trapping inhaled particles, and maintaining airway hygiene through mucociliary clearance. Dysfunction or hyperplasia of the bronchial glandular epithelium is implicated in diseases such as asthma, chronic bronchitis, and cystic fibrosis, due to abnormal mucus production and secretion[3][4][5][8]. Bronchial glandular epithelium is not a single molecule or protein, nor a canonical pharmacological target, but a morphological tissue structure. If you seek drug targets, you should instead reference specific cell-surface receptors, ion channels, or proteins expressed by these epithelial cells, such as muscarinic receptors, CFTR, or mucins (e.g., MUC5B)[3][4].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Bronchial glandular epithelium.